FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980990870> ?p ?o ?g. }

• W2980990870 endingPage "352" @default.
• W2980990870 startingPage "346" @default.
• W2980990870 abstract "Abstract This study aimed to evaluate the bioequivalence (BE) of 2 formulations of the 10‐mg rivaroxaban tablet. The study was a randomized, open‐label, 4‐period, crossover study that included 28 healthy subjects in fasting or fed conditions. The pharmacokinetic parameters were determined based on the concentrations of rivaroxaban using high‐performance liquid chromatography with a tandem mass spectrometer detector. In each of the 4 study periods with fasting or fed conditions, a single dose of test or reference product was administered. Rivaroxaban concentrations in plasma were determined using a validated liquid chromatography with a tandem mass spectrometer detector method. The pharmacokinetic parameters assessed were the area under the plasma concentration‐time curve (AUC 0‐t , AUC 0‐∞ ), the peak plasma concentration of the drug (C max ), time to achieve C max , elimination half‐life, within‐subject variability of test drug, and within‐subject variability of reference drug. The geometric mean ratio (90%CI) of the test drug/reference drug for rivaroxaban was 90.38% to 103.60% for AUC 0‐t in fasting conditions and 90.13% to 100.42% in fed conditions. The AUC 0‐∞ s were 89.94% to 102.50% and 90.14% to 100.45% under fasting and fed conditions, respectively. The C max values were 90.58% to 105.01% and 96.36% to 108.07% in these 2 conditions, respectively. All 90%CIs for test drug/reference drug geometric mean ratio were ≤2.5. The 90%CIs for test/reference AUC ratio and C max ratio were within the acceptable range for BE. There were no adverse events encountered during this BE study. The study's results indicated that the 2 formulations of the rivaroxaban tablet were bioequivalent." @default.
• W2980990870 created "2019-10-25" @default.
• W2980990870 creator A5003062724 @default.
• W2980990870 creator A5003065832 @default.
• W2980990870 creator A5005477512 @default.
• W2980990870 creator A5029484872 @default.
• W2980990870 creator A5034507101 @default.
• W2980990870 creator A5040643319 @default.
• W2980990870 creator A5057313063 @default.
• W2980990870 creator A5057741416 @default.
• W2980990870 creator A5063568775 @default.
• W2980990870 creator A5072897283 @default.
• W2980990870 date "2019-10-14" @default.
• W2980990870 modified "2023-10-02" @default.
• W2980990870 title "Bioequivalence Study of 2 Formulations of Rivaroxaban, a Narrow‐Therapeutic‐Index Drug, in Healthy Chinese Subjects Under Fasting and Fed Conditions" @default.
• W2980990870 cites W1564607482 @default.
• W2980990870 cites W1984935828 @default.
• W2980990870 cites W2000407236 @default.
• W2980990870 cites W2006941607 @default.
• W2980990870 cites W2017582897 @default.
• W2980990870 cites W2069707383 @default.
• W2980990870 cites W2167182965 @default.
• W2980990870 cites W2562965755 @default.
• W2980990870 cites W2771949431 @default.
• W2980990870 cites W2809064859 @default.
• W2980990870 cites W2912688339 @default.
• W2980990870 cites W2925297114 @default.
• W2980990870 doi "https://doi.org/10.1002/cpdd.742" @default.
• W2980990870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31610099" @default.
• W2980990870 hasPublicationYear "2019" @default.
• W2980990870 type Work @default.
• W2980990870 sameAs 2980990870 @default.
• W2980990870 citedByCount "6" @default.
• W2980990870 countsByYear W29809908702021 @default.
• W2980990870 countsByYear W29809908702022 @default.
• W2980990870 countsByYear W29809908702023 @default.
• W2980990870 crossrefType "journal-article" @default.
• W2980990870 hasAuthorship W2980990870A5003062724 @default.
• W2980990870 hasAuthorship W2980990870A5003065832 @default.
• W2980990870 hasAuthorship W2980990870A5005477512 @default.
• W2980990870 hasAuthorship W2980990870A5029484872 @default.
• W2980990870 hasAuthorship W2980990870A5034507101 @default.
• W2980990870 hasAuthorship W2980990870A5040643319 @default.
• W2980990870 hasAuthorship W2980990870A5057313063 @default.
• W2980990870 hasAuthorship W2980990870A5057741416 @default.
• W2980990870 hasAuthorship W2980990870A5063568775 @default.
• W2980990870 hasAuthorship W2980990870A5072897283 @default.
• W2980990870 hasConcept C105795698 @default.
• W2980990870 hasConcept C112705442 @default.
• W2980990870 hasConcept C126322002 @default.
• W2980990870 hasConcept C142724271 @default.
• W2980990870 hasConcept C185592680 @default.
• W2980990870 hasConcept C204787440 @default.
• W2980990870 hasConcept C27081682 @default.
• W2980990870 hasConcept C2776301958 @default.
• W2980990870 hasConcept C2778661090 @default.
• W2980990870 hasConcept C2779161974 @default.
• W2980990870 hasConcept C2780035454 @default.
• W2980990870 hasConcept C33923547 @default.
• W2980990870 hasConcept C40222840 @default.
• W2980990870 hasConcept C42404028 @default.
• W2980990870 hasConcept C43617362 @default.
• W2980990870 hasConcept C71924100 @default.
• W2980990870 hasConcept C76318530 @default.
• W2980990870 hasConcept C87813604 @default.
• W2980990870 hasConcept C98274493 @default.
• W2980990870 hasConceptScore W2980990870C105795698 @default.
• W2980990870 hasConceptScore W2980990870C112705442 @default.
• W2980990870 hasConceptScore W2980990870C126322002 @default.
• W2980990870 hasConceptScore W2980990870C142724271 @default.
• W2980990870 hasConceptScore W2980990870C185592680 @default.
• W2980990870 hasConceptScore W2980990870C204787440 @default.
• W2980990870 hasConceptScore W2980990870C27081682 @default.
• W2980990870 hasConceptScore W2980990870C2776301958 @default.
• W2980990870 hasConceptScore W2980990870C2778661090 @default.
• W2980990870 hasConceptScore W2980990870C2779161974 @default.
• W2980990870 hasConceptScore W2980990870C2780035454 @default.
• W2980990870 hasConceptScore W2980990870C33923547 @default.
• W2980990870 hasConceptScore W2980990870C40222840 @default.
• W2980990870 hasConceptScore W2980990870C42404028 @default.
• W2980990870 hasConceptScore W2980990870C43617362 @default.
• W2980990870 hasConceptScore W2980990870C71924100 @default.
• W2980990870 hasConceptScore W2980990870C76318530 @default.
• W2980990870 hasConceptScore W2980990870C87813604 @default.
• W2980990870 hasConceptScore W2980990870C98274493 @default.
• W2980990870 hasIssue "3" @default.
• W2980990870 hasLocation W29809908701 @default.
• W2980990870 hasOpenAccess W2980990870 @default.
• W2980990870 hasPrimaryLocation W29809908701 @default.
• W2980990870 hasRelatedWork W2013847231 @default.
• W2980990870 hasRelatedWork W2026222539 @default.
• W2980990870 hasRelatedWork W2050557946 @default.
• W2980990870 hasRelatedWork W2055974197 @default.
• W2980990870 hasRelatedWork W2087796686 @default.
• W2980990870 hasRelatedWork W2091435156 @default.
• W2980990870 hasRelatedWork W2913025776 @default.
• W2980990870 hasRelatedWork W3145656073 @default.
• W2980990870 hasRelatedWork W4367835432 @default.

• next